All In Biotech

Drug Trial Radar · NCT06226571

A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

96

Actual

Start

May 21, 2024

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
Syndax PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of revumenib in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.

Conditions

  • Acute Myeloid Leukemias

Interventions

  • RevumenibDrug

    Participants will receive revumenib orally during Induction, Consolidation, and Maintenance until meeting criteria for discontinuation.

  • Chemotherapy RegimenDrug

    Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.

  • HiDACDrug

    Consolidation: Participants will receive HiDAC IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: Number of Participants with Dose-limiting ToxicitiesTime frame: Up to Day 42
  2. Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 through 30 days after final dose (up to approximately 3 years)

Locations

48 sites in 6 countries. Site status is shown where the registry gives one.

  • City of Hope

    Goodyear, Arizona

  • UCLA Medical Hematology

    Burbank, California

  • City of Hope Medical Center

    Duarte, California

  • AdventHealth Blood & Marrow Transplant Center

    Orlando, Florida

  • Tampa General Hospital

    Tampa, Florida

  • Emory Winship Cancer Institute

    Atlanta, Georgia

  • University of Illinois

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • University of Louisville Health Brown Cancer Center

    Louisville, Kentucky

  • Norton Cancer Institute, St. Matthews Campus

    Louisville, Kentucky

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Allina Health Cancer Institute

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Institution name: Northwell Health-Brany

    Lake Success, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • SUNY Upstate Medical University

    Syracuse, New York

  • East Carolina University

    Greenville, North Carolina

  • Atrium Health Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Oregon Health and Science University- Center for Hematologic Malignancies

    Portland, Oregon

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • MUSC Hollings Cancer Center (HCC)

    Charleston, South Carolina

  • Baylor University Medical Center

    Dallas, Texas

  • The University of Texas, MD Anderson Cancer Center

    Houston, Texas

  • LDS Hospital - Intermountain Healthcare

    Salt Lake City, Utah

  • West Virginia University

    Morgantown, West Virginia

  • Royal Adelaide Hospital

    Adelaide, Australia

  • The Alfred Hospital, Victoria

    Melbourne, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Australia

  • Northern Hospital, Victoria

    Epping, Victoria, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • Gordon and Leslie Diamond Health Care Center

    Vancouver, British Columbia, Canada

  • The Sir Mortimer B. Davis Jewish General Hospital

    Montreal, Quebec, Canada

  • University Medical Center Utrecht

    Utrecht, Netherlands

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital San Pedro de Alcantara

    Cáceres, Spain

  • Hospital Universitario Virgen de Las Nieves

    Granada, Spain

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.